Breast Imaging

Should You Order a Bone Scan for Asymptomatic, Newly Diagnosed Stage I Breast Cancer?

·
Should You Order a Bone Scan for Asymptomatic, Newly Diagnosed Stage I Breast Cancer?

You are in your clinic, reviewing the pathology report for a patient with a newly diagnosed T1c, N0, M0 invasive ductal carcinoma of the breast. The diagnosis is Stage I, and the patient is entirely asymptomatic, with no bone pain or other constitutional symptoms. As you plan the initial workup before definitive local treatment, the question of systemic staging arises: should you order imaging to rule out distant bone metastases? This article provides a detailed clinical workflow for this specific scenario, explaining why the American College of Radiology (ACR) finds imaging for bone metastases to be Usually Not Appropriate in this low-risk population.

Who Fits This Clinical Scenario?

This guidance applies to a very specific patient population: those with a new diagnosis of Stage I breast cancer who are asymptomatic. The key inclusion criteria are:

  • New Diagnosis: This workflow is for the initial workup, not for later surveillance after treatment has been completed.
  • Stage I Disease: This typically includes tumors that are 2 cm or smaller and have not spread to the lymph nodes (T1, N0, M0). The risk of distant metastases at diagnosis is exceptionally low in this group.
  • Asymptomatic for Metastases: The patient must have no signs or symptoms suggestive of bone involvement, such as new, persistent, or localized bone pain; unexplained fractures; or constitutional symptoms like unexplained weight loss.

It is crucial to distinguish this scenario from others that may seem similar. This guidance does not apply if:

  • The patient is symptomatic: A patient with new, focal bone pain requires a different workup, as the pre-test probability of a metastasis is higher.
  • The patient has more advanced disease: Patients with Stage II or III breast cancer have a higher risk of distant metastases, and systemic staging with imaging is often warranted.
  • The goal is surveillance: The imaging strategy for asymptomatic surveillance after initial treatment is covered in a separate ACR variant. This article focuses only on the initial workup at the time of diagnosis.

What Diagnoses Are You Working Up in This Scenario?

In this clinical context, the primary goal of ordering bone imaging would be to rule out a single, critical diagnosis: osseous (bone) metastases. However, the decision to order a test must balance the low probability of finding this diagnosis against the high probability of encountering other, benign findings that can complicate the clinical picture.

Bone Metastases: This is the target diagnosis. In Stage I breast cancer, the incidence of bone metastases at the time of initial diagnosis is extremely low. The rationale for not imaging is based on this low pre-test probability; the potential harms of the workup are considered to outweigh the potential benefits.

Benign Bone Lesions: A significant concern with systemic imaging in a low-risk population is the high likelihood of discovering incidental benign findings. These can include bone islands (enostoses), fibrous cortical defects, or enchondromas. While harmless, their discovery on a bone scan or PET/CT can trigger a cascade of further, often invasive, investigations to rule out malignancy, causing significant patient anxiety and healthcare costs.

Degenerative and Arthritic Changes: Whole-body bone scans are notoriously non-specific. Increased radiotracer uptake is common in areas of osteoarthritis, degenerative disc disease, or prior trauma. These findings can be difficult to distinguish from metastases, often leading to indeterminate reports that necessitate further imaging, such as targeted MRI or CT, to clarify.

Why Is Imaging for Bone Metastases Usually Not Appropriate?

For an asymptomatic patient with newly diagnosed Stage I breast cancer, the ACR Appropriateness Criteria panel has determined that all common imaging modalities for detecting bone metastases are Usually Not Appropriate. This recommendation is rooted in the principle of avoiding low-yield testing that carries a greater risk of harm (from radiation, false positives, and diagnostic cascades) than benefit.

The evidence consistently shows that the risk of occult bone metastases in this specific patient group is exceedingly low, often less than 1%. Ordering a screening test in such a low-prevalence setting dramatically increases the chance that a positive result is a false positive.

Let’s review the specific modalities and their ratings:

  • Radiography skeletal survey: Rated Usually Not Appropriate. A skeletal survey involves multiple X-rays covering the axial and proximal appendicular skeleton. It is relatively insensitive for detecting early, small-volume metastatic disease, which typically must cause significant cortical bone destruction to become visible. It also imparts a non-trivial radiation dose (adult RRL ☢☢☢ 1-10 mSv) for a test with very low diagnostic yield in this scenario.
  • Bone scan (whole body scintigraphy): Rated Usually Not Appropriate. While more sensitive than a skeletal survey for detecting blastic metastases, a whole-body bone scan has poor specificity. It detects areas of increased bone turnover, which can be caused by a wide range of benign conditions, including arthritis, healing fractures, and infection. The high rate of false-positive or equivocal findings often triggers a cascade of unnecessary follow-up tests. The radiation dose is also a consideration (adult RRL ☢☢☢ 1-10 mSv).
  • FDG-PET/CT (whole body): Rated Usually Not Appropriate. This is the most sensitive imaging modality for detecting widespread metastatic disease, but it is not recommended for this low-risk scenario. It carries the highest radiation dose of the three options (adult RRL ☢☢☢☢ 10-30 mSv) and is also prone to false positives from inflammatory or infectious processes. Its use for routine staging in asymptomatic Stage I patients is a clear example of over-imaging.

What’s Next? Downstream Workflow After the Imaging Decision

The recommended clinical pathway for this scenario is to forgo systemic bone imaging. The downstream workflow focuses on proceeding with definitive treatment and educating the patient.

  • If You Follow Guidelines (No Imaging): This is the recommended path. The next step is to proceed with the planned local therapy (e.g., lumpectomy or mastectomy, sentinel node biopsy) and adjuvant radiation or systemic therapy (chemotherapy, endocrine therapy, targeted therapy) as indicated by the tumor’s biology. The patient should be counseled on the extremely low risk of distant disease at this stage and educated on the specific symptoms (e.g., new, persistent, localized bone pain) that should prompt them to seek medical attention in the future.
  • If Imaging Is Performed and Is Negative: While this may provide reassurance, it comes at the cost of unnecessary radiation exposure and healthcare expenditure. The clinical management—proceeding with local and systemic therapy—remains unchanged.
  • If Imaging Is Performed and Is Positive or Indeterminate: This is the primary harm the guidelines seek to avoid. An indeterminate finding on a bone scan or a suspicious lesion on a PET/CT will necessitate further workup. This typically involves targeted imaging with MRI or CT for better anatomic characterization. If the lesion remains suspicious, a bone biopsy may be required to confirm or exclude metastasis. This entire cascade introduces procedural risks, delays definitive breast cancer treatment, and causes substantial patient anxiety, most often for what turns out to be a benign finding.

Pitfalls to Avoid (and When to Get Help)

Navigating this decision requires careful clinical judgment. Here are common pitfalls to avoid:

  • Ordering Scans for Patient Anxiety: While patient anxiety is understandable, ordering a low-yield test is often not the best way to address it. A clear conversation about the very low risks in Stage I disease is more appropriate than exposing the patient to the risks of a diagnostic cascade.
  • Over-interpreting Non-specific Symptoms: Be cautious not to misclassify a patient as symptomatic. Vague, migratory aches and pains or pre-existing arthritis are not indications for a metastatic workup. The red flag is new, persistent, and localized pain.
  • Ignoring Tumor Biology: While this guidance applies to Stage I disease generally, clinicians should remain vigilant. However, even for more aggressive subtypes like triple-negative breast cancer, the risk of distant metastases in T1N0 disease remains very low.

If your patient develops true red-flag symptoms, such as severe and unremitting back pain, point tenderness over a bone, or a pathologic fracture, they no longer fit this asymptomatic scenario. At that point, you should escalate care and pursue targeted imaging based on their symptoms.

Related ACR Topics and Tools

For a comprehensive overview of all clinical variants related to imaging in Stage I breast cancer, and for tools to help with ordering decisions, the following resources are available:

Frequently Asked Questions

What if my patient with Stage I breast cancer has non-specific aches and pains?

General, non-specific, or migratory aches and pains are common and do not typically warrant a metastatic workup. The key symptom to watch for is new, persistent, and localized bone pain that is not relieved by rest. If symptoms are consistent with pre-existing conditions like arthritis, this guidance for asymptomatic patients still applies.

Is there ever a role for bone imaging in Stage I breast cancer?

For routine staging in an asymptomatic patient, no. However, if a patient with Stage I disease develops specific symptoms concerning for bone metastases (e.g., severe, localized back pain) or has unexplained elevated alkaline phosphatase or hypercalcemia, then targeted imaging would become appropriate. The patient would no longer fit the ‘asymptomatic’ criteria.

Why is a PET/CT scan not recommended if it’s the most sensitive test?

While FDG-PET/CT is highly sensitive, its use in a low-risk population like asymptomatic Stage I breast cancer leads to more harm than good. The pre-test probability of disease is so low that a positive finding is more likely to be a false positive (due to inflammation, infection, or benign tumors) than a true metastasis. This triggers invasive workups for benign conditions, while adding significant radiation exposure and cost.

My patient is very anxious and is asking for a scan for peace of mind. How should I respond?

This is a common and challenging situation. The best approach is patient education. Explain clearly that for their specific situation (Stage I, asymptomatic), the risk of having bone metastases is extremely low. Then, explain the risks of the scan itself, including radiation and the high chance of a false-positive result that could lead to more tests, anxiety, and even biopsies for a benign issue. Framing the decision as a way to avoid unnecessary harm is often effective.

Does this ‘no imaging’ recommendation apply to all subtypes of Stage I breast cancer, like triple-negative or HER2-positive?

Yes, major clinical guidelines (including NCCN and ASCO) recommend against routine systemic staging for clinical Stage I and II breast cancer, regardless of subtype, in the absence of signs or symptoms of metastatic disease. While some subtypes have a higher risk of recurrence over time, the incidence of detectable distant metastases at the initial T1N0 diagnosis remains very low across all subtypes.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026